Steve Aselage Biography and Net Worth

Steve Aselage was appointed to the Board in January 2019. Mr. Aselage most recently served as Chief Executive Officer of Travere Therapeutics, a biopharmaceutical company specializing in identifying, developing, and delivering life-changing therapies to people living with rare diseases, which he joined in 2012. He has more than 40 years of experience in the biopharmaceutical industry, including substantial rare disease, commercial, and business development experience. From 2005 to 2012, Mr. Aselage served as Executive Vice President and Chief Business Officer of BioMarin. Prior to BioMarin, Mr. Aselage held positions of increasing responsibility at a number of companies, including Bristol Laboratories, Genentech, and Sangstat. He continues to serve as chairman of Acer Therapeutics and on the advisory council of the University of Notre Dame Department of Science.

What is Steve Aselage's net worth?: The estimated net worth of Steve Aselage is at least $16,975.00 as of May 24th, 2024. Mr. Aselage owns 2,500 shares of BioCryst Pharmaceuticals stock worth more than $16,975 as of April 7th. This net worth estimate does not reflect any other assets that Mr. Aselage may own. Learn More about Steve Aselage's net worth.
How do I contact Steve Aselage?: The corporate mailing address for Mr. Aselage and other BioCryst Pharmaceuticals executives is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals can also be reached via phone at (919) 859-1302 and via email at investorrelations@biocryst.com. Learn More on Steve Aselage's contact information.
Has Steve Aselage been buying or selling shares of BioCryst Pharmaceuticals?: Steve Aselage has not been actively trading shares of BioCryst Pharmaceuticals during the past quarter. Most recently, on Friday, May 24th, Steve Aselage bought 2,500 shares of BioCryst Pharmaceuticals stock. The stock was acquired at an average cost of $6.40 per share, with a total value of $16,000.00. Following the completion of the transaction, the director now directly owns 2,500 shares of the company's stock, valued at $16,000. Learn More on Steve Aselage's trading history.
Who are BioCryst Pharmaceuticals' active insiders?: BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Steve Aselage (Director), Yarlagadda Babu (Insider), Alane Barnes (Insider), Anthony Doyle (CFO), Steven Galson (Director), Nancy Hutson (Director), Alan Levin (Director), Amy McKee (Director), Vincent Milano (Director), Machelle Sanders (Director), William Sheridan (Insider), Jon Stonehouse (CEO), and Helen Thackray (Chief Research & Development Officer). Learn More on BioCryst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of BioCryst Pharmaceuticals?: During the last twelve months, BioCryst Pharmaceuticals insiders bought shares 6 times. They purchased a total of 103,601 shares worth more than $596,337.56. During the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 13,289 shares worth more than $82,486.00. The most recent insider tranaction occured on June, 24th when Director Amy E Mckee sold 8,600 shares worth more than $54,352.00. Insiders at BioCryst Pharmaceuticals own 4.8% of the company. Learn More about insider trades at BioCryst Pharmaceuticals.
Information on this page was last updated on 6/24/2024.

Steve Aselage Insider Trading History at BioCryst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/24/2024	Buy	2,500	$6.40	$16,000.00	2,500
5/22/2019	Buy	3,000	$3.57	$10,710.00	5,000
3/12/2019	Buy	2,000	$8.30	$16,600.00	2,000

Steve Aselage Buying and Selling Activity at BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Company Overview

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Today's Range

Now: $6.79

$6.43

$7.05

50 Day Range

MA: $8.14

$6.83

$9.39

2 Week Range

Now: $6.79

$4.03

$9.50

Volume

4,368,676 shs

Average Volume

2,784,867 shs

Market Capitalization

$1.42 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.75